New Options in Diabetic Retinopathy: Let the Data Be Your Guide

0.50 CME
0.50 ABO MOC
30 MINS
$0 FEE
SAVE
New Options

Overview

Provider Statement

This continuing medical education activity is provided by Vindico Medical Education.


Support Statement

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.  


Activity Description

Early diagnosis and prompt treatment of diabetic retinopathy (DR) has been shown to effectively prevent vision loss. Until recently, panretinal photocoagulation was the primary management approach for DR. However, clinical trial data from pinnacle studies utilizing anti-vascular endothelial growth factor (anti-VEGF) therapy in patients with diabetic macular edema have demonstrated that anti-VEGF therapy is also an effective treatment option for patients with DR. Specific data on the optimal use of anti-VEGF agents to treat DR have emerged from both initial studies establishing the effectiveness of anti-VEGF in this setting and subsequent clinical trials. In this CME activity, experts in the field will evaluate new findings pertaining to the optimization of treatment dosing and management of patients with DR, compare treatment protocols for proliferative versus nonproliferative DR, and assess treatment regimens for their ability to achieve regression of DR.


Target Audience

The intended audience for this activity is retina specialists and other health care professionals involved in the management of patients with diabetic retinopathy (DR).


Learning Objective(s)

Upon successful completion of this activity, participants should be better able to:

  • Evaluate new findings pertaining to the optimization of treatment dosing and management of patients with diabetic retinopathy.
  • Compare treatment protocols for proliferative versus non-proliferative diabetic retinopathy.
  • Assess treatment regimens for their ability to achieve regression of diabetic retinopathy.

Activity Chair

Peter K. Kaiser, MD
Chaney Family Endowed Chair in Ophthalmology Research
Professor of Ophthalmology
Cole Eye Institute
Cleveland Clinic
Lerner College of Medicine
Cleveland, OH


Faculty

Darius M. Moshfeghi, MD
Professor
Chief, Retina Division
Byers Eye Institute
Stanford University School of Medicine
Palo Alto, CA


Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP


Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABO

Successful completion of this CME activity, which is defined as answering ALL the posttest questions and includes participation in the evaluation component, enables the learner to satisfy the Lifelong Learning requirements for the American Board of Ophthalmology’s Maintenance of Certification (ABO MOC) program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting MOC credit. Upon successful completion, learners who opt-in by providing their ABO ID and DOB (MM/DD) will earn MOC credits equivalent to the amount of CME credits claimed for the activity. The CME activity provider will submit learner completion information to the ACCME for the purpose of granting ABO MOC credits within 30 days of activity completion.

This enduring material is approved for 1 year from the date of original release, April 9, 2020, through April 8, 2021.


How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each of the questions. A satisfactory score is defined as answering 2 out of 3 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.


Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.

The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.

Activity Chair and Faculty report the following relationship(s)

Peter K. Kaiser, MD
Consulting Fee: Aerie, Aerpio, Alcon, Allegro, Allergan, Bausch + Lomb, Bayer, Biogen Idec, Boehringer Ingelheim, Chengdu Kanghong, Clearside, Eyevensys, Formycon/BioEq GmbH, Galecto Biotech, Galimedix, Hospira, Irenix, jCyte, Kala, Kodiak, NGM Biopharmaceuticals, Novartis, Ocugenix, Omeros, Opthea, Oxurion (ThromboGenics), Regeneron, Regenxbio, Retinal Sciences, Roivant, Santen, SciFluor, Shire, Spark Therapeutics, Stealth Biotherapeutics, Verena (Digisight), Zeiss

Darius M. Moshfeghi, MD
Receipt of Intellectual Property/Patent Holder: dSentz, Linc, Pr3vent, Promisight, Versl
Consulting Fee: Bayer, Congruence Medical, Iconic Therapeutics, Novartis, Regeneron, Visunex
Ownership Interest: dSentz, Grand Legend Technologies, Linc, Pr3vent, Promisight, Pykus, Versl, Visunex
Scientific Advisory Board: Akebia, Pykus
Steering Committee: Bayer, Iconic Therapeutics, Regeneron

Reviewer reports the following relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.


Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.


Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.


CME Questions?

Contact us at cme@vindicoCME.com